These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 34454676)

  • 1. Current and future status of JAK inhibitors.
    McLornan DP; Pope JE; Gotlib J; Harrison CN
    Lancet; 2021 Aug; 398(10302):803-816. PubMed ID: 34454676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis].
    Frøling M; Mikkelsen C; Eggertsen PP; Stern M; van de Looij A; Deleuran B
    Ugeskr Laeger; 2017 Oct; 179(44):. PubMed ID: 29084618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.
    Samadi A; Ahmad Nasrollahi S; Hashemi A; Nassiri Kashani M; Firooz A
    J Dermatolog Treat; 2017 Sep; 28(6):476-483. PubMed ID: 28024126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK-STAT inhibitors: Immersing therapeutic approach for management of rheumatoid arthritis.
    Singh S; Singh S
    Int Immunopharmacol; 2020 Sep; 86():106731. PubMed ID: 32590315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature.
    Hunter AM; Bose P
    Expert Opin Pharmacother; 2024 Jul; 25(10):1391-1404. PubMed ID: 39067001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting myeloproliferative neoplasms with JAK inhibitors.
    Pardanani A; Tefferi A
    Curr Opin Hematol; 2011 Mar; 18(2):105-10. PubMed ID: 21245760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis.
    Yates M; Mootoo A; Adas M; Bechman K; Rampes S; Patel V; Qureshi S; Cope AP; Norton S; Galloway JB
    Arthritis Rheumatol; 2021 May; 73(5):779-788. PubMed ID: 33174384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.
    Nash P; Kerschbaumer A; Dörner T; Dougados M; Fleischmann RM; Geissler K; McInnes I; Pope JE; van der Heijde D; Stoffer-Marx M; Takeuchi T; Trauner M; Winthrop KL; de Wit M; Aletaha D; Baraliakos X; Boehncke WH; Emery P; Isaacs JD; Kremer J; Lee EB; Maksymowych WP; Voshaar M; Tam LS; Tanaka Y; van den Bosch F; Westhovens R; Xavier R; Smolen JS
    Ann Rheum Dis; 2021 Jan; 80(1):71-87. PubMed ID: 33158881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK-STAT inhibitors for the treatment of immunomediated diseases.
    Serra López-Matencio JM; Morell Baladrón A; Castañeda S
    Med Clin (Barc); 2019 May; 152(9):353-360. PubMed ID: 30527218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK inhibition in inflammatory bowel disease.
    Olivera P; Danese S; Peyrin-Biroulet L
    Expert Rev Clin Immunol; 2017 Jul; 13(7):693-703. PubMed ID: 28164724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel treatment for psoriatic arthritis: Janus kinase inhibitors.
    Chen M; Dai SM
    Chin Med J (Engl); 2020 Apr; 133(8):959-967. PubMed ID: 32209886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Janus Kinase Inhibitors Differentially Inhibit Specific Cytokine Signals in the Mesenteric Lymph Node Cells of Inflammatory Bowel Disease Patients.
    Hindmarch DC; Malashanka S; Shows DM; Clarke AS; Lord JD
    J Crohns Colitis; 2024 Apr; 18(4):628-637. PubMed ID: 37855324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting.
    Miyazaki Y; Nakano K; Nakayamada S; Kubo S; Inoue Y; Fujino Y; Tanaka Y
    Ann Rheum Dis; 2021 Sep; 80(9):1130-1136. PubMed ID: 33827788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deregulated JAK/STAT signalling in lymphomagenesis, and its implications for the development of new targeted therapies.
    Scott LM; Gandhi MK
    Blood Rev; 2015 Nov; 29(6):405-15. PubMed ID: 26123794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK inhibitors in dermatology: The promise of a new drug class.
    Damsky W; King BA
    J Am Acad Dermatol; 2017 Apr; 76(4):736-744. PubMed ID: 28139263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway.
    Fitton J; Melville AR; Emery P; Nam JL; Buch MH
    Rheumatology (Oxford); 2021 Sep; 60(9):4048-4054. PubMed ID: 33331938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib.
    Patel AA; Odenike O
    Curr Hematol Malig Rep; 2020 Dec; 15(6):409-418. PubMed ID: 32780250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.
    Pardanani A; Vannucchi AM; Passamonti F; Cervantes F; Barbui T; Tefferi A
    Leukemia; 2011 Feb; 25(2):218-25. PubMed ID: 21079613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New generation small-molecule inhibitors in myeloproliferative neoplasms.
    Passamonti F; Maffioli M; Caramazza D
    Curr Opin Hematol; 2012 Mar; 19(2):117-23. PubMed ID: 22227528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of the use of Janus kinase inhibitors in the treatment of scarring alopecia.
    Nohria A; Desai D; Shapiro J; Bordone L; Lo Sicco K
    Int J Dermatol; 2024 Jun; 63(6):e105-e110. PubMed ID: 38571280
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.